TORONTO, Oct. 7, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. REUNREUN (“reunion” or the “company“), a leader in the development of novel psychedelic medicines dedicated to developing innovative therapeutic solutions for mental disorders through the development of proprietary serotonin receptor agonist compounds, announced today that Ronan Levy has joined as a director of the company and Paula Amy Hewitt have resigned as General Counsel & Corporate Secretary effective October 7, 2022.
The company would like to sincerely thank Mr. Levy and Ms. Hewitt for their contributions to the company and wish them the best in their future endeavors.
In addition, the Company has appointed Greg Mayes, President and Chief Executive Officer, Reunion, as a Director and Donna Wong, Chief Financial Officer, Reunion, as Corporate Secretary, effective October 7, 2022.
About Reunion Neuroscience Inc. (formerly Field Trip Health Ltd.)
Reunion is a leader in the development of novel psychedelic medicines and is committed to innovative therapeutic solutions for mental illness through the development of proprietary serotonin receptor agonist compounds. The Company’s lead compound, RE-104 (formerly known as FT-104), is a proprietary, novel psychedelic drug being developed for postpartum and treatment-resistant depression as a potentially fast-acting antidepressant with sustained efficacy. Reunion is also developing the FT-200 series, which includes compounds with the potential for more selective serotonin receptor activity with reduced psychoactivity for potential use in more chronic treatment paradigms and indications.
Learn more at https://www.investors.reunionneuro.comand https://www.reunionneuro.com.
follow us on LinkedIn, Twitter and Instagram.
To be added to the Reunion Neuroscience email list, please send an email reunion@kcsa.com with “REUN” in the subject line.
Cautionary Statement Regarding Forward-Looking Information
This press release contains forward-looking information (within the meaning of Canadian securities laws and the…
